Show simple item record

dc.contributor.authorChaturvedi, A
dc.contributor.authorAraujo Cruz, M M
dc.contributor.authorJyotsana, N
dc.contributor.authorSharma, A
dc.contributor.authorGoparaju, R
dc.contributor.authorSchwarzer, A
dc.contributor.authorGörlich, K
dc.contributor.authorSchottmann, R
dc.contributor.authorStruys, E A
dc.contributor.authorJansen, E E
dc.contributor.authorRohde, C
dc.contributor.authorMüller-Tidow, C
dc.contributor.authorGeffers, Robert
dc.contributor.authorGöhring, G
dc.contributor.authorGanser, A
dc.contributor.authorThol, F
dc.contributor.authorHeuser, M
dc.date.accessioned2017-09-08T09:28:30Z
dc.date.available2017-09-08T09:28:30Z
dc.date.issued2016-08
dc.identifier.citationEnantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. 2016, 30 (8):1708-15 Leukemiaen
dc.identifier.issn1476-5551
dc.identifier.pmid27063596
dc.identifier.doi10.1038/leu.2016.71
dc.identifier.urihttp://hdl.handle.net/10033/621098
dc.description.abstractCanonical mutations in IDH1 and IDH2 produce high levels of the R-enantiomer of 2-hydroxyglutarate (R-2HG), which is a competitive inhibitor of α-ketoglutarate (αKG)-dependent enzymes and a putative oncometabolite. Mutant IDH1 collaborates with HoxA9 to induce monocytic leukemia in vivo. We used two mouse models and a patient-derived acute myeloid leukemia xenotransplantation (PDX) model to evaluate the in vivo transforming potential of R-2HG, S-2HG and αKG independent of the mutant IDH1 protein. We show that R-2HG, but not S-2HG or αKG, is an oncometabolite in vivo that does not require the mutant IDH1 protein to induce hyperleukocytosis and to accelerate the onset of murine and human leukemia. Thus, circulating R-2HG acts in a paracrine manner and can drive the expansion of many different leukemic and preleukemic clones that may express wild-type IDH1, and therefore can be a driver of clonal evolution and diversity. In addition, we show that the mutant IDH1 protein is a stronger oncogene than R-2HG alone when comparable intracellular R-2HG levels are achieved. We therefore propose R-2HG-independent oncogenic functions of mutant IDH1 that may need to be targeted in addition to R-2HG production to exploit the full therapeutic potential of IDH1 inhibition.
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshAnimalsen
dc.subject.meshClone Cellsen
dc.subject.meshGlutaratesen
dc.subject.meshHeterograftsen
dc.subject.meshHomeodomain Proteinsen
dc.subject.meshHumansen
dc.subject.meshIsocitrate Dehydrogenaseen
dc.subject.meshIsomerismen
dc.subject.meshKetoglutaric Acidsen
dc.subject.meshLeukemia, Myeloid, Acuteen
dc.subject.meshMiceen
dc.subject.meshMutationen
dc.subject.meshOncogenesen
dc.subject.meshParacrine Communicationen
dc.titleEnantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate.en
dc.typeArticleen
dc.contributor.departmentHelmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.en
dc.identifier.journalLeukemiaen
refterms.dateFOA2018-06-12T21:25:33Z
html.description.abstractCanonical mutations in IDH1 and IDH2 produce high levels of the R-enantiomer of 2-hydroxyglutarate (R-2HG), which is a competitive inhibitor of α-ketoglutarate (αKG)-dependent enzymes and a putative oncometabolite. Mutant IDH1 collaborates with HoxA9 to induce monocytic leukemia in vivo. We used two mouse models and a patient-derived acute myeloid leukemia xenotransplantation (PDX) model to evaluate the in vivo transforming potential of R-2HG, S-2HG and αKG independent of the mutant IDH1 protein. We show that R-2HG, but not S-2HG or αKG, is an oncometabolite in vivo that does not require the mutant IDH1 protein to induce hyperleukocytosis and to accelerate the onset of murine and human leukemia. Thus, circulating R-2HG acts in a paracrine manner and can drive the expansion of many different leukemic and preleukemic clones that may express wild-type IDH1, and therefore can be a driver of clonal evolution and diversity. In addition, we show that the mutant IDH1 protein is a stronger oncogene than R-2HG alone when comparable intracellular R-2HG levels are achieved. We therefore propose R-2HG-independent oncogenic functions of mutant IDH1 that may need to be targeted in addition to R-2HG production to exploit the full therapeutic potential of IDH1 inhibition.


Files in this item

Thumbnail
Name:
Chaturvedi et al.pdf
Size:
1.635Mb
Format:
PDF
Description:
free PMC's author's manuscript

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-sa/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/